相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis
Ting Deng et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer
Georg Dimcevski et al.
JOURNAL OF CONTROLLED RELEASE (2016)
FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study
S. J. Rombouts et al.
JOURNAL OF CANCER (2016)
Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy
PeiJian Peng et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival
Akiyoshi Kasuga et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Comparative Efficacy and Tolerability of Three Treatments in Old People with Osteoporotic Vertebral Compression Fracture: A Network Meta-Analysis and Systematic Review
Ling-Xiao Chen et al.
PLOS ONE (2015)
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
Kentaro Sudo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer
Yee Chao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Graphical Tools for Network Meta-Analysis in STATA
Anna Chaimani et al.
PLOS ONE (2013)
Assessing the Quality of Randomized Controlled Urological Trials Conducted by Korean Medical Institutions
Jae Hoon Chung et al.
KOREAN JOURNAL OF UROLOGY (2013)
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
Y. Nakai et al.
BRITISH JOURNAL OF CANCER (2012)
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
Masato Ozaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies
Yu-Kang Tu et al.
JOURNAL OF CLINICAL PERIODONTOLOGY (2012)
Pancreatic Adenocarcinoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study
A. Inal et al.
NEOPLASMA (2012)
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer
Kentaro Sudo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
PHASE II STUDY OF ORAL S-1 AND CONCURRENT RADIOTHERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER
Kentaro Sudo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Georgia Salanti et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
Elias Assaf et al.
ONCOLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
V. Hess et al.
ANNALS OF ONCOLOGY (2010)
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study
Giuseppe Colucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan adjuvant study group of pancreatic cancer (JASPAC-01)
Atsuyuki Maeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2008)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Richard Herrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
G. P. Stathopoulos et al.
BRITISH JOURNAL OF CANCER (2006)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
K. Nakamura et al.
BRITISH JOURNAL OF CANCER (2006)
Randomized scheduling feasibility study of S-I for adjuvant chemotherapy in advanced head and neck cancer
M Tsukuda et al.
BRITISH JOURNAL OF CANCER (2005)
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
H Oettle et al.
ANNALS OF ONCOLOGY (2005)
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)
F Di Costanzo et al.
BRITISH JOURNAL OF CANCER (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer -: A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study
T Conroy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study
GP Stathopoulos et al.
ANNALS OF ONCOLOGY (2004)
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
CMR Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial
W Scheithauer et al.
ANNALS OF ONCOLOGY (2003)
分享论文
